Si Liu
7 Papers
1 Citations
Si Liu is an academic researcher. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 2, co-authored 7 publications.
Chat about Author
Papers
Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A)
TL;DR: A locally advanced lung cancer patient with dMMR/MSI-H/TMB-H tumor and selective loss of PMS2 by immunohistochemistry was presented and the diagnosis of LS was made based on genetic analysis of this variant and literature review.
Abstract 5517: Addition of PD-1 antibody camrelizumab overcame resistance to trastuzumab plus chemotherapy in a HER2-positive, metastatic gallbladder cancer patient
TL;DR: A HER2-positive metastatic GBC patient who was refractory to trastuzumab plus chemotherapy but experienced significant clinical benefit after the addition of camrelizumab is presented, and it is demonstrated that immune-related adverse events (irAEs) associated with camrelIZumab can be managed with an anti-VEGF agent apatinib.
1
Safety, tolerability, pharmacokinetics and preliminary efficacy of MIL93, an anti-Claudin18.2 monoclonal antibody, in patients with advanced solid tumors: A phase 1 clinical study.
Jing Huang,Ying Yong Wang,Feng Wang,Shikai Wu,Yi Zheng,Jianping Xu,Dongmei Lan,Minli Wei,Si Liu +8 more
TL;DR: The primary objectives were the safety and tolerability, dose limiting toxicities (DLTs) and maximum tolerated dose (MTD) of MIL93, and secondary objectives included pharmacokinetics, immunogenicity and preliminary efficacy.
Abstract 5777: Germline variants of cancer predisposition genes in a large cohort of Chinese sarcoma patients
TL;DR: Germline testing of 148-cancer predisposition genes revealed novel predisposition variants associated with sarcoma, and some of them can serve as therapeutic targets for future clinical investigation and provided proof of principle that Sarcoma patients may benefit from genetic counseling and participate in genomically-matched clinical trials.
Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications
Zhiming Zhao,Xiaomo Li,Fei Wang,Yong Xu,Si Liu,Quanli Han,Zhiying Yang,Zhu-Zeng Yin,Qu Liu,Haidong Tan,Tonghui Ma,Shuang Si,Jia Huang,Hongling Yuan,Wei Li,Rong Liu +15 more
TL;DR: The authors reported that approximately 90% of pancreatic ductal adenocarcinoma (PDAC) cases are driven by the untargetable non-G12C KRAS mutations, and only a small subset of patients are eligible for FDA-approved precision therapies.